The Association between SARS-CoV-2 Infection and Diabetic Ketoacidosis in Patients with New-Onset Diabetes: A Retrospective Study from a Diabetic Center in Saudi Arabia.

COVID-19 DKA DM Jazan Saudi Arabia diabetes

Journal

Pediatric reports
ISSN: 2036-749X
Titre abrégé: Pediatr Rep
Pays: Switzerland
ID NLM: 101551542

Informations de publication

Date de publication:
29 Nov 2022
Historique:
received: 17 10 2022
revised: 20 11 2022
accepted: 24 11 2022
entrez: 22 12 2022
pubmed: 23 12 2022
medline: 23 12 2022
Statut: epublish

Résumé

Various reports described new-onset diabetes during or after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with no previous history of diabetes or glucocorticoid use. Further, SARS-CoV-2 could increase the risk of diabetes, including diabetic ketoacidosis (DKA). However, data on the relationship between new-onset diabetes and COVID-19 are still limited in our region. Thus, we aimed in this study to evaluate the association between new-onset diabetes and DKA in patients with COVID-19. A retrospective, cross-sectional study was conducted at a diabetic center in Jazan province, Saudi Arabia, between 2020 and 2021. Demographic data, COVID-19 status, and DKA incidence were collected and verified manually from diabetic patients' medical records. Data were analyzed using a t-test and chi-square test. We included 54 diabetic patients diagnosed during the COVID-19 pandemic, with a median age of 17 years. The majority of patients were females (57.4%). About 38.8% were diagnosed with COVID-19, and 16.6% reported having DKA. About 33.3% of the patients who experienced DKA reported being COVID-19-positive. However, only 6% of patients who denied contracting SARS-CoV-2 developed DKA ( Patients with newly diagnosed diabetes due to COVID-19 seem at a higher risk of developing DKA. Further epidemiological and molecular studies are required for a better understanding of the correlation between DKA in patients with diabetes and COVID-19.

Sections du résumé

BACKGROUND BACKGROUND
Various reports described new-onset diabetes during or after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with no previous history of diabetes or glucocorticoid use. Further, SARS-CoV-2 could increase the risk of diabetes, including diabetic ketoacidosis (DKA). However, data on the relationship between new-onset diabetes and COVID-19 are still limited in our region. Thus, we aimed in this study to evaluate the association between new-onset diabetes and DKA in patients with COVID-19.
METHODS METHODS
A retrospective, cross-sectional study was conducted at a diabetic center in Jazan province, Saudi Arabia, between 2020 and 2021. Demographic data, COVID-19 status, and DKA incidence were collected and verified manually from diabetic patients' medical records. Data were analyzed using a t-test and chi-square test.
RESULTS RESULTS
We included 54 diabetic patients diagnosed during the COVID-19 pandemic, with a median age of 17 years. The majority of patients were females (57.4%). About 38.8% were diagnosed with COVID-19, and 16.6% reported having DKA. About 33.3% of the patients who experienced DKA reported being COVID-19-positive. However, only 6% of patients who denied contracting SARS-CoV-2 developed DKA (
CONCLUSIONS CONCLUSIONS
Patients with newly diagnosed diabetes due to COVID-19 seem at a higher risk of developing DKA. Further epidemiological and molecular studies are required for a better understanding of the correlation between DKA in patients with diabetes and COVID-19.

Identifiants

pubmed: 36548203
pii: pediatric14040060
doi: 10.3390/pediatric14040060
pmc: PMC9780883
doi:

Types de publication

Journal Article

Langues

eng

Pagination

519-527

Références

Arterioscler Thromb Vasc Biol. 2004 May;24(5):816-23
pubmed: 14976002
J Diabetes Complications. 2022 Nov;36(11):108336
pubmed: 36228563
Diabetes Care. 2020 Nov;43(11):e170-e171
pubmed: 32816997
Diabetes Technol Ther. 2021 Jul;23(7):517-521
pubmed: 33544017
Diabet Med. 2006 Jun;23(6):623-8
pubmed: 16759303
Pediatr Diabetes. 2022 Feb;23(1):10-18
pubmed: 34865288
Cureus. 2021 Mar 31;13(3):e14223
pubmed: 33948412
Am J Emerg Med. 2020 Nov;38(11):2491.e3-2491.e4
pubmed: 32536476
Diabetes Ther. 2021 Feb;12(2):461-464
pubmed: 33367980
Diabet Med. 2021 Sep;38(9):e14640
pubmed: 34245598
Nat Rev Endocrinol. 2020 Jun;16(6):297-298
pubmed: 32242089
J Clin Res Pediatr Endocrinol. 2022 Mar 21;14(3):267-274
pubmed: 35308015
Int J Mol Sci. 2020 May 10;21(9):
pubmed: 32397684
Acta Diabetol. 2010 Sep;47(3):193-9
pubmed: 19333547
J Pediatr Endocrinol Metab. 2022 May 24;35(7):859-866
pubmed: 35607289
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Diabetologia. 1998 Feb;41(2):127-33
pubmed: 9498644
Diabetes Res Clin Pract. 2020 Apr;162:108132
pubmed: 32234504
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
J Clin Virol. 2017 Nov;96:26-31
pubmed: 28934695
Adv Clin Exp Med. 2021 Feb;30(2):127-134
pubmed: 33599404
J Clin Res Pediatr Endocrinol. 2022 May 31;14(3):366-367
pubmed: 35633641
Microorganisms. 2020 Sep 23;8(10):
pubmed: 32977495
Diabetes Care. 2014 Jan;37 Suppl 1:S81-90
pubmed: 24357215
Cell Metab. 2021 Aug 3;33(8):1577-1591.e7
pubmed: 34081913
Diabetes Res Clin Pract. 2021 Aug;178:108959
pubmed: 34280467
Int J Pediatr. 2018 May 8;2018:9408370
pubmed: 29853923
Front Endocrinol (Lausanne). 2021 Apr 01;12:669302
pubmed: 33868185
JAMA. 2020 Aug 25;324(8):801-804
pubmed: 32702751
Acta Biomed. 2020 Jul 13;91(3):ahead of print
pubmed: 32921748
Diabetes Metab Syndr. 2021 Jan-Feb;15(1):447-454
pubmed: 33592371
Diabetes Res Clin Pract. 2020 Sep;167:108382
pubmed: 32853686
Diabetes Care. 2020 Nov;43(11):2870-2872
pubmed: 32778554
Emerg Infect Dis. 2016 Jan;22(1):49-55
pubmed: 26692185
Nat Rev Endocrinol. 2021 Jul;17(7):379-380
pubmed: 33875855
Cell Mol Immunol. 2020 Jun;17(6):613-620
pubmed: 32203189
J Clin Med. 2021 Sep 14;10(18):
pubmed: 34575251
Diabetes Metab Res Rev. 2020 Mar 31;:e33213321
pubmed: 32233018
J Infect Public Health. 2021 Jul;14(7):832-838
pubmed: 34118732
Acta Biomed. 2020 Sep 07;91(3):e2020033
pubmed: 32921727
Cell Stem Cell. 2020 Jul 2;27(1):125-136.e7
pubmed: 32579880
Int J Environ Res Public Health. 2021 Nov 26;18(23):
pubmed: 34886175
Cell Metab. 2021 Aug 3;33(8):1565-1576.e5
pubmed: 34081912

Auteurs

Eman Hurissi (E)

Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.

Mohammed Alameer (M)

Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.

Fadiyah Ageeli (F)

Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.

Maram Allami (M)

Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.

Mohammed Alharbi (M)

Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.

Hussam Suhail (H)

Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.

Hadeel Albeishy (H)

Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.

Omar Oraibi (O)

Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.

Mohammed Somaili (M)

Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.

Abdulrahman Hummadi (A)

Jazan Endocrinology and Diabetes Center, Ministry of Health, Jazan 82722, Saudi Arabia.

Abdulaziz H Alhazmi (AH)

Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.

Classifications MeSH